- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03953157
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
Improving Health of Women on Aromatase Inhibitors
Study Overview
Status
Conditions
- Arthralgia
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Postmenopausal
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To recruit an ethnically, racially and culturally diverse sample of postmenopausal women diagnosed with estrogen receptor positive breast cancer who are currently taking aromatase inhibitor (AI), establish eligibility, and randomly allocate 20 participants to a two-arm parallel intervention trial.
II. Conduct baseline measurements of: body composition and bone mineral density, reported muscle and joint pain; inflammatory, cardiovascular and bone health markers contained in blood serum; and, cardiovascular function.
III. Conduct a three month anti-inflammatory dietary intervention in one arm, and bone strengthening exercise intervention in the other study arm.
IV. At completion of these 3-month interventions, evaluate changes since baseline of body composition, bone density, reported muscle and joint pain, and inflammatory and cardiovascular measurements within each intervention arm, and preliminarily contrast changes between intervention arms.
V. Utilize results from both intervention arms to design a larger 2x2 randomized factorial trial designed to assess effects of anti-inflammatory diet, effects of bone promoting exercise, and combined diet and exercise intervention effects on joint and muscle pain, inflammatory markers, bone mineral density, and cardiovascular measures.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive a controlled anti-inflammatory diet over 12 weeks.
ARM II: Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
After completion of study, patients are followed up at 1 week.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gail Thames
- Phone Number: 310-825-0453
- Email: gthames@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA / Jonsson Comprehensive Cancer Center
-
Contact:
- Catherine L. Carpenter, PhD
- Phone Number: 310-825-8499
- Email: ccarpenter@sonnet.ucla.edu
-
Principal Investigator:
- Catherine L. Carpenter, PhD
-
Contact:
- Gail Thames
- Phone Number: 310-825-0453
- Email: gthames@mednet.ucla.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 6 months since breast cancer diagnosis up to 2 years since diagnosis.
- Diagnosed with localized breast cancer, up to stage IIIa.
- Has been taking aromatase inhibitor (AIs) for at least six months.
- Has been experiencing mild to moderate arthralgia (joint pain) for at least 2 months determined by the Brief Pain Inventory (BPI).
- At least 6 months post chemotherapy or radiation treatment.
- Subjects must be in good health as determined by medical history, physical examination, iDXA scan and clinical laboratory measurements.
- Postmenopausal either natural or surgical or postmenopausal caused by ovarian suppression treatments administered to premenopausal women.
- Currently taking aromatase inhibitor medication.
Exclusion Criteria:
- Diagnosed with metastatic breast cancer.
- Currently undergoing chemotherapy or radiation treatment.
- Food allergies of any kind, or any medical condition requiring mandatory dietary restrictions.
- A bone mineral density (BMD) T score less than -1, or fracture since taking AIs, or current use of glucocorticoids.
- Taking bisphosphonates or any other medication for bone loss.
- Significant cardiac, pulmonary, renal, liver or psychiatric disease.
- Currently undergoing or engaging in a regular exercise program.
- Muscular, orthopedic, or cardiovascular limitations that would prevent full participation in exercise.
- Body mass index (BMI) greater than 40 kg/m^2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (dietary intervention)
Patients receive a controlled anti-inflammatory diet over 12 weeks.
|
Ancillary studies
Receive dietary intervention
Other Names:
|
Experimental: Arm II (exercise intervention)
Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
|
Ancillary studies
Receive exercise intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone mineral density
Time Frame: Baseline up to 1 week post intervention
|
Will be scanned by dual x-ray absorptiometry (iDXA).
|
Baseline up to 1 week post intervention
|
Joint and muscle pain
Time Frame: Baseline up to 1 week post intervention
|
Joint and muscle pain will be measured by the Brief Pain Inventory, a frequently administered assessment for studies of women on aromatase inhibitors (AIs).
Participants will be asked about use of pain medication and supplements such as chondroitin and glucosamine.
Subjects will also fill out standard visual analog scales to rate intensity of pain ranging from 1 to 10, as well as locate source of pain on standardized human figures available from International Society of Anesthetic Pharmacology.
Additionally grip strength, a common marker of functional muscle and joint weakness, will be assessed using a dynamometer.
|
Baseline up to 1 week post intervention
|
Inflammatory markers
Time Frame: Baseline up to 1 week post intervention
|
Fasting blood samples will be collected at baseline and end of intervention.
Serum markers, IL-6, Il-8, TNF-?, MCP-1, hs-CRP, leptin, TGFbeta, IL-1beta, and CRP will be quantified.
|
Baseline up to 1 week post intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Catherine L Carpenter, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-001926 (Other Identifier: UCLA / Jonsson Comprehensive Cancer Center)
- NCI-2019-02909 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthralgia
-
Victoria ShanmugamCompletedArthritis | Synovitis | Arthralgia SyndromeUnited States
-
Grant JonesGenzyme, a Sanofi CompanyWithdrawnArthralgiaUnited States
-
The Center for Applied Health Sciences, LLCNatreon, Inc.Completed
-
University Hospital, LilleCompleted
-
Hospital de Clinicas de Porto AlegreUnknown
-
AHS Cancer Control AlbertaNot yet recruitingArthritis | Arthralgia
-
Uppsala UniversityCompleted
-
AHS Cancer Control AlbertaRecruitingArthritis | ArthralgiaCanada
-
Riphah International UniversityRecruiting
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation